United States of America. The Institute for Safe Medication Practices has received 3 reports of serious adverse events following the use of hydroxyamfetamine/tropicamide (ParemydR) opthalmic solution for routine diagnostic purposes. One patient sustained a fatal myocardial infarction, another developed ventricular fibrillation and a third developed hypotension, bradycardia and syncope, which required intervention.

The manufacturer, Allergan Inc, is advising health professionals to bear in mind the drug’s sympathomimetic/parasympatholytic pharmacology, since compounds such as ParemydR have known potential effects on the cardiac system.

Reference: ISMP Medication Safety Alert! Vol. 2, Issue 14, 16 July 1997.

.
.